TRDA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Entrada Therapeutics Inc (TRDA) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the stock has potential upside due to its innovative platform and upcoming catalysts, the company's poor financial performance, lack of recent positive news, and neutral trading trends suggest caution. The technical indicators are mixed, and there is no strong signal from proprietary trading tools. It would be prudent to monitor the stock for better entry points or further positive developments.
The technical indicators show mixed signals. The MACD is slightly positive, indicating mild bullish momentum, but the RSI is neutral, suggesting no clear trend. Moving averages are bullish, with SMA_5 > SMA_20 > SMA_200, but the stock is trading near its pivot level of 13.687, with resistance at 14.352 and support at 13.023. The stock has an 80% chance of minor gains (1.5%) in the next day but is likely to decline in the next week (-4.3%) and month (-7.62%).
Analysts are optimistic about the company's platform, with several buy ratings and price target increases, including a potential 50% upside after the Q2 readout. The company's platform is seen as potentially first-in-class and best-in-class, targeting a significant addressable market in Duchenne Muscular Dystrophy.
The company's financial performance in Q4 2025 was extremely poor, with revenue dropping by 96.53% YoY, net income down 3562.78% YoY, and EPS declining by 3233.33% YoY. Additionally, there is no recent news or significant trading activity from insiders, hedge funds, or Congress. The stock is also expected to decline in the short to medium term based on historical patterns.
In Q4 2025, the company's revenue dropped by 96.53% YoY to $1,299,000, net income plummeted by 3562.78% YoY to -$39,164,000, and EPS fell by 3233.33% YoY to -$0.94. Despite a gross margin of 100%, the overall financial performance was extremely weak.
Analysts are generally positive, with multiple buy ratings and price target increases. Oppenheimer raised the price target to $23, Cantor Fitzgerald initiated coverage with an Overweight rating, and Guggenheim sees the stock potentially doubling by the end of 2026. However, these ratings are contingent on successful Q2 readouts and platform validation.
